Press Release: "TrialReach Rebrands as Antidote and Expands its Products to Include EHR Matching"
NEW YORK AND LONDON (September 20, 2016) – TrialReach, a digital health startup that connects patients and researchers to accelerate medical research, today unveiled a new brand, including a new company name: Antidote. Antidote is leading a collaborative effort to speed up the development of breakthrough treatments and potential cures by making medical research accessible and transparent to all. This new name speaks to the critical importance of breaking through the barriers that exist today between patients and researchers so that they can connect faster and better.
Despite the fact that there has never been a more exciting time in the history of medicine with the development of new treatments such as immunotherapy and stem cell transplants, there’s a major problem in medical research today: 85% of patients don’t know about clinical trials, and if they do, it’s very challenging to find trials for which they are qualified. This results in 80% of clinical trials being delayed or closed. It means that medical progress is slowed, and patients continue to wait for answers. Antidote believes that together we can solve this problem; accelerating medical research is a global mission that affects us all.
Antidote was founded on the notion that all patients should know about the option to take part in clinical trials – and that the information available about these trials should be clear and accessible. “With our new products and tools, we are poised to make a major impact on the speed of medical research by empowering patients to get involved,” said Pablo Graiver, Founder and CEO. “We couldn’t be more excited to share our new branding and refresh our commitment to the mission of Antidote.”
Antidote aims to improve the health of everyone, everywhere. As part of this mission, Antidote has launched Antidote Match, which uses natural language processing, artificial intelligence, and an army of medical annotators to make it easier than ever before for people to find their best clinical trial matches. In addition, Antidote Bridge is a free tool that gives researchers the opportunity to provide the key details that patients want and need when making clinical trial decisions. And, to make sure all patients know about opportunities to take part in medical research, Antidote has built Connect Network, the first online network of patient organizations, online health portals, and advocacy groups who share in the mission to accelerate medical research by connecting patients to trials. Through this network, Antidote’s study information reaches more than 20 million patients per month. Antidote will be announcing details of their new EHR product shortly.
To see how the new Antidote brand has come to life, and to learn more about Match, Bridge, and Connect, please visit http://www.antidote.me.
###
About Antidote
Antidote is a digital health company on a mission. Their aim is to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need them.
In a world where 80% of clinical trials are delayed or closed due to lack of awareness, Antidote uses cutting-edge technology to match the right patients with the right trials, helping medical researchers make faster progress, and offering new treatment options to patients in need.
Antidote was launched as TrialReach in 2010, and is based in the US and UK.
This is a global effort to advance healthcare for everyone. To find out how you can help shape medical history, visit http://www.antidote.me.
Media Contacts
Sarah Kerruish (UK)
Chief Strategy and Growth Officer, Antidote
+44 7546364484
sarah@antidote.me
Lisa Brockway (US)
Director of Communications, Antidote
(215) 872-2917
lisa@antidote.me